DSIP

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide consisting of nine amino acids in the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (abbreviated WAGGDASGE), with a molecular weight of 849 daltons. ^(1,2) The peptide was first isolated in 1977 by the Schoenenberger-Monnier research group at the University of Basel, Switzerland, from the cerebral venous blood of rabbits during low-frequency electrical stimulation of the intralaminar thalamic nuclei. ^(1,2) This discovery established DSIP as one of the earliest identified endogenous sleep factors, a naturally produced substance that directly influences sleep regulation.

DSIP has been found in both free and bound forms throughout the central nervous system and peripheral tissues. In the brain, it is present in the hypothalamus, limbic system, and pituitary gland, where it co-localizes (also spelled co-localizes) with multiple peptide and non-peptide mediators, including ACTH, melanocyte-stimulating hormone (MSH), thyroid-stimulating hormone (TSH), and melanin-concentrating hormone (MCH). ⁽¹⁾ Outside the CNS, DSIP is abundant in gut secretory cells and in the pancreas, where it co-localizes with glucagon. ⁽¹⁾ It is also present in human breast milk at concentrations of 10-30 ng/mL, a fact that has led researchers to speculate about its role in infant sleep regulation. ⁽⁴⁾

DSIP’s structure is unique among known peptide families, sharing no sequence homology with other established neuropeptide groups. ^(1,3) Its gene and precursor protein have not been identified, and the precise site of synthesis remains unknown. However, evidence suggests that glucocorticoids regulate it and interact with components of the MAPK (mitogen-activated protein kinase) signaling cascade. ⁽¹⁾ This unresolved biology has been described in the literature as “a still unresolved riddle,” reflecting both the peptide’s established biological activity and the gaps in understanding its endogenous regulation. ⁽³⁾

DSIP possesses two unusual pharmacological properties for a peptide. First, it freely crosses the blood-brain barrier, enabling systemic administration (including subcutaneous injection) to produce central nervous system effects. ⁽⁴⁾ Second, it is absorbed from the gut without being fully denatured by digestive enzymes, which is atypical for peptides and has implications for potential oral delivery routes. ⁽⁴⁾

DSIP is not FDA-approved for any therapeutic indication. In September 2023, the FDA classified DSIP as a Category 2 bulk drug substance, preventing compounding pharmacies from preparing it for patients. ⁽⁵⁾ A potential reclassification was announced in February 2026, though no formal FDA policy change had been published as of March 2026. ⁽⁶⁾ DSIP is not approved by the MHRA (UK) or TGA (Australia) for any indication. It is not classified as a controlled substance in any of these jurisdictions. Healius supplies DSIP as a lyophilized (also referred to as lyophilized) powder in 15mg vials, intended strictly for laboratory and research applications.

DSIP acts as a sleep-promoting substance rather than a sedative, a distinction that is fundamental to understanding its pharmacology. ^(2,4) Conventional sedatives (benzodiazepines, barbiturates, Z-drugs) suppress neural activity broadly, producing sleep through generalized (also spelled generalized) CNS depression. DSIP, by contrast, modulates sleep architecture by enhancing the natural mechanisms that produce slow-wave (delta) sleep, the deepest stage of the sleep cycle associated with physical restoration, growth hormone release, immune function, and memory consolidation. ^(2,4)

The mechanistic pathways through which DSIP influences sleep involve multiple neurotransmitter systems. Research has demonstrated interactions with NMDA glutamate receptors, GABAergic pathways, and serotonergic systems. ^(1,4) DSIP stimulates acetyltransferase activity through alpha-1 adrenergic receptors in rats and influences cerebral MAO-A (monoamine oxidase A) activity, which regulates the metabolism of serotonin, norepinephrine (also spelled noradrenaline), and dopamine. ^(1,7) Through these interactions, DSIP modulates the neurotransmitter balance that determines sleep onset, sleep depth, and sleep stage transitions.

A critical pharmacological characteristic is that DSIP does not need to be administered immediately before sleep to be effective. Research has shown that a dose of DSIP given during the day will promote improved sleep that night and for several nights thereafter. ⁽⁴⁾ This delayed and sustained effect distinguishes DSIP from all conventional sleep aids. It suggests a “programming” or “normalizing” (also spelled “normalizing”) influence on sleep-wake regulation rather than a direct sedative action. ^(4,7)

DSIP also exhibits pronounced circadian rhythm effects. Brain and plasma DSIP concentrations show marked diurnal variation, with low levels in the morning and higher levels in the afternoon, correlating with the natural circadian drive toward sleep in the evening. ⁽⁴⁾ Administration of DSIP does not induce tolerance, meaning that repeated use does not require escalating doses to maintain effect, a significant advantage over many conventional sleep medications. ⁽⁴⁾

Beyond sleep, DSIP has broad neuroendocrine activity. It reduces basal levels of corticotropin (ACTH), the pituitary hormone that drives cortisol release, while stimulating the secretion of luteinizing (also spelled luteinizing) hormone (LH), somatoliberin (GHRH), and somatotropin (growth hormone). ^(1,8) This hormonal profile, combining cortisol suppression with GH promotion, aligns with the physiological hormonal environment that characterizes deep, restorative sleep.

DSIP has been the subject of multiple human clinical investigations, providing a rare body of direct human data for a research peptide. ^(2,7,9)

In a landmark double-masked study, six healthy volunteers received 25 nmol/kg DSIP intravenously in the morning. ⁽⁹⁾ Subjects immediately reported a “feeling of sleep pressure,” and total sleep time increased by 59% within a 130-minute interval following administration compared to placebo. ⁽⁹⁾ Delayed effects on subsequent night sleep included shorter sleep onset latency, reduced percentage of Stage 1 (light) sleep, and improved sleep efficiency. Notably, the researchers found no evidence of sedation in the classical pharmacological sense, concluding that “DSIP in humans is efficacious by sustaining natural sleep functions.” ⁽⁹⁾

A double-blind study in 16 chronic insomniac patients (25 nmol/kg IV on three consecutive evenings) demonstrated higher sleep efficiency and shorter sleep latency with DSIP compared to placebo. ⁽²⁾ The researchers described the effects as statistically significant but modest in this short-term protocol, concluding that DSIP may have greater benefit in longer treatment courses or specific insomnia subtypes rather than as a universal short-term intervention. ⁽²⁾

The stress-modulating properties of DSIP represent a significant secondary research axis. DSIP has been demonstrated to counteract experimentally induced stress in animal models, acting as a stress-protective adaptogen. ^(1,7) It normalizes brain metabolism disrupted by chronic amphetamine treatment, a model relevant to schizophrenia-like conditions. ⁽⁸⁾ In a clinical pilot study, DSIP administered intravenously over 5 consecutive days, followed by 5 injections every 48-72 hours, significantly reduced pain levels in 6 of 7 patients with chronic pain conditions, including migraine, vasomotor headaches, chronic tinnitus, and psychogenic pain. ⁽⁷⁾ A simultaneous significant reduction in concomitant depressive symptoms was observed, suggesting that DSIP’s stress-modulatory effects extend to mood regulation. ⁽⁷⁾

A 2024 study published in Frontiers in Pharmacology demonstrated that a DSIP-Blood Brain Barrier Crossing Peptide (DSIP-CBBBP) fusion peptide showed improved sleep-promoting and neurotransmitter-balancing effects in a PCPA-induced insomnia mouse model, with measurable changes in serotonin (5-HT), glutamate, dopamine, and melatonin levels. ⁽¹⁰⁾ This represents ongoing research into optimizing DSIP’s delivery and efficacy through structural modification.

Additional research has investigated DSIP in substance withdrawal contexts. Studies have reported pronounced effects on withdrawal symptoms, including pain states in alcoholics and opiate addicts, alongside improvement in psychomotor performance and concentration capacity. ⁽⁷⁾ These findings, while preliminary, suggest that DSIP’s effects on neurotransmitter homeostasis may have applications beyond sleep regulation.

DSIP’s biological activity extends well beyond sleep promotion, encompassing longevity, pain modulation, and anti-tumor (also spelled anti-tumor) effects, as documented in published research. ^(1,8)

In a geroprotective study on mice, lifetime administration of DSIP produced striking results: spontaneous tumor incidence decreased 2.6-fold, age-related decline in estrous (also spelled estrous) function was slowed, chromosomal aberrations in bone marrow cells decreased by 22.6%, and maximum lifespan increased by 24.1% compared to controls. ⁽¹⁾ These effects parallel some of the geroprotective properties documented for Epithalon, another peptide from the same research era, though through distinct mechanisms.

Analgesic effects have been documented in both animal and human studies. DSIP has a potent antinociceptive effect when administered intracerebroventricularly or intracisternally in mice. ⁽¹⁾ The clinical pilot study in chronic pain patients (migraine, tinnitus, psychogenic pain) showed significant pain reduction in 6 of 7 patients with concurrent improvement in depressive symptoms. ⁽⁷⁾ The mechanism appears to involve modulation of endogenous opioid-peptidergic systems rather than direct opioid receptor agonism, distinguishing DSIP from conventional analgesics. ⁽⁷⁾

Anticonvulsant activity has been demonstrated in rat models of epilepsy, where DSIP significantly decreased both the incidence and duration of seizures, suggesting potential applications in epilepsy research. ⁽¹⁾ Neuroprotective effects have also been documented: a 2021 study published in MDPI Molecules demonstrated that intranasal DSIP administration over 8 days accelerated recovery of motor functions following focal stroke in rats. ⁽¹¹⁾

The breadth of DSIP’s biological activity, spanning sleep regulation, stress protection, hormone modulation, pain relief, anti-cancer effects, neuroprotection, and longevity, has led researchers to describe it as a “multifunctional regulatory peptide” rather than simply a sleep factor. ^(8,11) This multifunctionality likely reflects its widespread tissue distribution and interaction with multiple signaling systems (NMDA, GABAergic, serotonergic, MAPK, opioidergic).

The comparison between DSIP and melatonin is one of the most frequently searched topics in sleep peptide research, and the distinction is important for protocol design.

Melatonin is a hormone produced by the pineal gland that regulates the timing of the circadian sleep-wake cycle. It signals to the body that it is time to sleep by binding to MT1 and MT2 receptors in the suprachiasmatic nucleus, the brain’s master circadian clock. Melatonin is effective for sleep onset and circadian rhythm adjustment (jet lag, shift work) but has limited effects on sleep depth or slow-wave sleep architecture.

DSIP targets a fundamentally different aspect of sleep. Rather than regulating when you sleep, DSIP influences how deeply you sleep by promoting slow-wave (delta) sleep, the stage associated with physical restoration, growth hormone release, and immune function. ^(2,4) DSIP exhibits greater activity when sleep is disturbed and minimal effects in healthy subjects without sleep disruption, consistent with a modulatory rather than sedative mechanism. ⁽⁴⁾

The practical implication for research: Melatonin is a tool for circadian timing problems. DSIP is the tool for sleep quality and depth problems. Some protocols combine both compounds, using melatonin to set the circadian window and DSIP to enhance the restorative quality of sleep within that window. This complementary approach addresses both dimensions of sleep regulation simultaneously.

1. Wikipedia. Delta-sleep-inducing peptide. Comprehensive, source-based overview of discovery, distribution, mechanism, sleep effects, analgesic activity, anti-cancer, and geroprotective data. Updated November 2025.

2. Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP on disturbed sleep in humans. Double-blind study in 16 chronic insomniac patients. Experientia. 1981.

3. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006. PubMed: 16539679.

4. Pollard BJ, Pomfrett CJD. Delta sleep-inducing peptide. European Journal of Anaesthesiology. 2001; 18:419-422. Comprehensive clinical review: BBB crossing, oral absorption, breast milk presence, half-life, circadian variation, no tolerance, ACE inhibitor interaction.

5. FDA. Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding. September 2023. DSIP is classified as Category 2.

6. RFK Jr. / HHS announcement regarding potential reclassification of Category 2 peptides. February 27, 2026. Formal FDA policy change not yet published as of March 2026.

7. Larbig W, et al. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. European Neurology. 1984. PubMed: 6548970.

8. DSIP neuroendocrine effects: reduces ACTH, stimulates LH, somatoliberin, and somatotropin secretion. Iyer et al. 1988 (GH release). Multiple Russian pharmacological studies on stress-protective and adaptogenic activity.

9. Schneider-Helmert D, Schoenenberger GA. Acute and delayed effects of DSIP on human sleep behavior. Double-masked crossover study in 6 volunteers. 25 nmol/kg IV. 59% increase in total sleep time. PubMed: 6895513.

10. Mu X, et al. Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Frontiers in Pharmacology. 2024; 15:1439536.

11. MDPI Molecules. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. 2021;26(17):5173. Intranasal DSIP for 8 days accelerated motor function recovery.

12. WADA Prohibited List 2026. DSIP is not explicitly listed. S0 (Non-Approved Substances) catch-all may apply.

This product is sold strictly for laboratory and research use only. It is not intended for human or animal consumption. It is not a dietary supplement, food, drug, or cosmetic. It is not intended to diagnose, treat, cure, or prevent any disease or condition. The buyer assumes all responsibility for the lawful use of this product in accordance with all applicable local, state, national, and international laws and regulations. By purchasing this product, the buyer confirms that they are a qualified researcher or are purchasing on behalf of a research institution.